Back to news
Poster
Wed. 29 June

In vivo PK/PD profile of Compound A

Share on

In vivo PK/PD profile of Compound A,
a brain penetrant, orally available potent and selective LRRK2 inhibitor, in rodent and non-rodent species

Authors

Arnaud François, Pascal Grondin, Guillaume Das Dores, Aurore Sors, Anne-Pascale Luzy, Cédric Vinson, Yann Lamotte, Petra Blom, Arnaud Le Tiran, Laurence Danober, Johannes Krupp, Jan Hoflack and Nicolas Ancellin

Objectives

Mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) are the most common genetic cause of Parkinson’s disease, leading to the development of LRRK2 inhibitors as potential therapeutic approach. Among them, Compound A has recently been selected as a potent, selective and brain-penetrant LRRK2 inhibitor. In order to confirm its in vivo target engagement and equipotency on wild type and G2019S LRRK2 mutants, several Pharmacokinetic/Pharmacodynamic (PK/PD) studies were performed in rodent and non-rodent species.

 

Prepared in collaboration with Servier

 

Please see the accompanying poster for the In vitro pharmacological profile of compound A

Read the others news

Financial
Press Release
Wed. 28 September
Oncodesign and OPM announce that Euronext Paris S.A. has authorised the admission to listing on Euronext Access+ market...

Subscribe to the OPM newsletter

Subscribe to the newsletter to not miss any news!